Free Trial

Geron (GERN) Competitors

$4.59
+0.70 (+17.99%)
(As of 06/7/2024 ET)

GERN vs. KDNY, ORGO, INZY, FHTX, ZIOP, RGEN, EXAS, EXEL, HALO, and IONS

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Chinook Therapeutics (KDNY), Organogenesis (ORGO), Inozyme Pharma (INZY), Foghorn Therapeutics (FHTX), ZIOPHARM Oncology (ZIOP), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.

Geron vs.

Geron (NASDAQ:GERN) and Chinook Therapeutics (NASDAQ:KDNY) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.

In the previous week, Geron had 21 more articles in the media than Chinook Therapeutics. MarketBeat recorded 21 mentions for Geron and 0 mentions for Chinook Therapeutics. Geron's average media sentiment score of 0.70 beat Chinook Therapeutics' score of 0.67 indicating that Geron is being referred to more favorably in the media.

Company Overall Sentiment
Geron Positive
Chinook Therapeutics Positive

Geron presently has a consensus target price of $6.50, suggesting a potential upside of 41.61%. Chinook Therapeutics has a consensus target price of $41.00, suggesting a potential upside of 1.51%. Given Geron's stronger consensus rating and higher possible upside, research analysts clearly believe Geron is more favorable than Chinook Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Chinook Therapeutics
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09

73.7% of Geron shares are held by institutional investors. Comparatively, 95.2% of Chinook Therapeutics shares are held by institutional investors. 3.1% of Geron shares are held by insiders. Comparatively, 16.8% of Chinook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Geron has higher earnings, but lower revenue than Chinook Therapeutics. Geron is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$240K11,343.61-$184.13M-$0.35-13.11
Chinook Therapeutics$6.13M473.15-$187.87M-$3.52-11.47

Geron received 454 more outperform votes than Chinook Therapeutics when rated by MarketBeat users. Likewise, 69.61% of users gave Geron an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote.

CompanyUnderperformOutperform
GeronOutperform Votes
481
69.61%
Underperform Votes
210
30.39%
Chinook TherapeuticsOutperform Votes
27
50.00%
Underperform Votes
27
50.00%

Chinook Therapeutics has a net margin of -4,199.93% compared to Geron's net margin of -38,730.00%. Chinook Therapeutics' return on equity of -58.28% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-38,730.00% -68.16% -47.26%
Chinook Therapeutics -4,199.93%-58.28%-44.72%

Geron has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Summary

Geron beats Chinook Therapeutics on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.31B$6.98B$5.23B$8.21B
Dividend YieldN/A2.66%2.73%4.04%
P/E Ratio-13.119.59111.0313.92
Price / Sales11,343.61278.812,437.0274.82
Price / CashN/A33.0035.1831.12
Price / Book9.985.654.964.32
Net Income-$184.13M$147.15M$110.34M$216.21M
7 Day Performance29.30%-2.05%-1.05%-1.43%
1 Month Performance20.47%-2.37%-0.61%-0.59%
1 Year Performance24.39%-5.74%2.92%3.58%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KDNY
Chinook Therapeutics
0 of 5 stars
$40.39
flat
$41.00
+1.5%
N/A$2.90B$6.13M-11.47214
ORGO
Organogenesis
3.8781 of 5 stars
$2.75
+2.6%
$4.83
+75.8%
-35.3%$355.29M$433.14M68.77862
INZY
Inozyme Pharma
3.273 of 5 stars
$4.63
-3.7%
$16.40
+254.2%
-22.4%$297.52MN/A-3.3859Positive News
FHTX
Foghorn Therapeutics
1.0422 of 5 stars
$6.01
-3.5%
$14.50
+141.3%
-24.0%$265.31M$34.15M-2.73116Gap Up
ZIOP
ZIOPHARM Oncology
0 of 5 stars
N/AN/AN/A$187.12MN/A-2.01105
RGEN
Repligen
4.4319 of 5 stars
$145.78
-1.9%
$197.75
+35.6%
-15.6%$8.30B$638.76M583.141,783Positive News
EXAS
Exact Sciences
4.3706 of 5 stars
$42.93
-3.9%
$93.07
+116.8%
-51.1%$8.24B$2.50B-32.526,600Analyst Revision
EXEL
Exelixis
4.9397 of 5 stars
$21.88
-1.4%
$26.13
+19.4%
+13.5%$6.72B$1.83B34.191,310Analyst Downgrade
Insider Selling
News Coverage
HALO
Halozyme Therapeutics
4.6153 of 5 stars
$50.85
-1.1%
$54.13
+6.4%
+46.5%$6.55B$829.25M21.01373Analyst Forecast
Analyst Revision
News Coverage
IONS
Ionis Pharmaceuticals
4.2571 of 5 stars
$38.95
-2.3%
$59.54
+52.9%
-3.9%$5.82B$788M-14.59927

Related Companies and Tools

This page (NASDAQ:GERN) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners